Identification of drug-resistant subpopulations in canine hemangiosarcoma

Veterinary and Comparative Oncology

Volumn 14, Issue 3, 2016, Pages e113-e125

  Khammanivong, A ^a   Gorden, B H ^a   Frantz, A M ^a   Graef, A J ^a   Dickerson, E B ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

ABC transporter; canine; drug resistance; hemangiosarcoma; side population

Indexed keywords

EID: 84980325817     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/vco.12114     Document Type: Article

References (43)

1. Hammer AS, Couto CG, Filppi J, Getzy D and Shank K. Efficacy and toxicity of VAC chemotherapy (vincristine, doxorubicin, and cyclophosphamide) in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 1991; 5: 160–166.
2. Ogilvie GK, Powers BE, Mallinckrodt CH and Withrow SJ. Surgery and doxorubicin in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 1996; 10: 379–384.
3. Sorenmo KU, Jeglum KA and Helfand SC. Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide. Journal of Veterinary Internal Medicine 1993; 7: 370–376.
4. Sorenmo K, Samluk M, Clifford C, Baez J, Barrett JS, Poppenga R, et al. Clinical and pharmacokinetic characteristics of intracavitary administration of pegylated liposomal encapsulated doxorubicin in dogs with splenic hemangiosarcoma. Journal of Veterinary Internal Medicine 2007; 21: 1347–1354.
5. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, et al. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. Journal of Veterinary Internal Medicine 2007; 21: 764–769.
6. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH and Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. Journal of Veterinary Internal Medicine 2007; 21: 113–120.
7. Holohan C, Van Schaeybroeck S, Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nature Reviews Cancer 2013; 13: 714–726.
8. Visvader JE and Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717–728.
9. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nature Medicine 1997; 3: 730–737.
10. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645–648.
11. Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML and Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes & Development 2003; 17: 3029–3035.
12. Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. New England Journal of Medicine 2004; 351: 657–667.
13. Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006; 442: 818–822.
14. Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 7950–7955.
15. Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61–74.
16. Iliopoulos D, Hirsch HA, Wang G and Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proceedings of the National Academy of Sciences of the United States of America 2011; 108: 1397–1402.
17. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 2003; 100: 3983–3988.
18. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Molecular Cancer 2006; 5: 67.
19. Zhang G, Ma L, Xie YK, Miao XB and Jin C. Esophageal cancer tumorspheres involve cancer stem-like populations with elevated aldehyde dehydrogenase enzymatic activity. Molecular Medicine Reports 2012; 6: 519–524.
20. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Research 2008; 68: 4311–4320.
21. Gorden BH, Kim JH, Sarver AL, Frantz AM, Breen M, Lindblad-Toh K, et al. Identification of three molecular and functional subtypes in canine hemangiosarcoma through gene expression profiling and progenitor cell characterization. American Journal of Pathology 2014; 184: 985–995.
22. Akhtar N, Padilla ML, Dickerson EB, Steinberg H, Breen M, Auerbach R, et al. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004; 6: 106–116.
23. Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GC and Modiano JF. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Experimental Hematology 2006; 34: 870–878.
24. Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE and Modiano JF. Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 2009; 4: e5549.
25. Schappa JT, Frantz AM, Gorden BH, Dickerson EB, Vallera DA and Modiano JF. Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors. International Journal of Cancer 2013; 133: 1936–1944.
26. Khammanivong A, Wang C, Sorenson BS, Ross KF and Herzberg MC. S100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma. PLoS One 2013; 8: e69395.
27. Alison MR, Lin WR, Lim SM and Nicholson LJ. Cancer stem cells: in the line of fire. Cancer Treatment Reviews 2012; 38: 589–598.
28. Boesch M, Reimer D, Rumpold H, Zeimet AG, Sopper S and Wolf D. DyeCycle Violet used for side population detection is a substrate of P-glycoprotein. Cytometry. Part A 2012; 81: 517–522.
29. Mathew G, Timm EA Jr, Sotomayor P, Godoy A, Montecinos VP, Smith GJ, et al. ABCG2-mediated DyeCycle Violet efflux defined side population in benign and malignant prostate. Cell Cycle 2009; 8: 1053–1061.
30. Sukowati CH, Rosso N, Pascut D, Anfuso B, Torre G, Francalanci P, et al. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma. BMC Gastroenterology 2012; 12: 160.
31. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105–127.
32. Bendayan R, Ronaldson PT, Gingras D and Bendayan M. In situ localization of P-glycoprotein (ABCB1) in human and rat brain. Journal of Histochemistry and Cytochemistry 2006; 54: 1159–1167.
33. Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Laboratory Investigation 2004; 84: 562–572.
34. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T. Opinion: migrating cancer stem cells – an integrated concept of malignant tumour progression. Nature Reviews Cancer 2005; 5: 744–749.
35. Sampieri K and Fodde R. Cancer stem cells and metastasis. Seminars in Cancer Biology 2012; 22: 187–193.
36. Vail DM and MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Investigation 2000; 18: 781–792.
37. Helfand SC. Canine hemangiosarcoma: a tumor of contemporary interest. Cancer Therapy 2008; 6: 457–462.
38. Goodell MA, Brose K, Paradis G, Conner AS and Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Journal of Experimental Medicine 1996; 183: 1797–1806.
39. Blacking TM, Waterfall M, Samuel K and Argyle DJ. Flow cytometric techniques for detection of candidate cancer stem cell subpopulations in canine tumour models. Veterinary and Comparative Oncology 2011; 10: 252–273.
40. She JJ, Zhang PG, Wang ZM, Gan WM and Che XM. Identification of side population cells from bladder cancer cells by DyeCycle Violet staining. Cancer Biology and Therapy 2008; 7: 1663–1668.
41. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, Bussey KJ, et al. Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 2004; 6: 129–137.
42. Lichtenauer UD, Shapiro I, Geiger K, Quinkler M, Fassnacht M, Nitschke R, et al. Side population does not define stem cell-like cancer cells in the adrenocortical carcinoma cell line NCI h295R. Endocrinology 2008; 149: 1314–1322.
43. Burkert J, Otto WR and Wright NA. Side populations of gastrointestinal cancers are not enriched in stem cells. Journal of Pathology 2008; 214: 564–573.